Register for the Live Webinar 21 Feb 3pm GMT In this free webinar Tom Parke discusses key questions about the use of quantitative decision making in drug development through simulation. Model based drug development produces estimates of the likely response to a drug, how should this be used to design a trial? The environment for [...]
When BiOxyDyn, (www.bioxydyn.com), a spin out company from Manchester University, needed to turn their innovative research and Intellectual Property (IP) in non-invasive medical imaging into a commercially robust, well-architected and fully-documented set of software tools, they called on Tessella’s unique blend of expertise in image analysis and scientific software engineering. The collaboration has enabled BiOxyDyn [...]
Focus group and survey confirm growing complexity of drug development and increasing adoption of smarter clinical trials Tom Parke, Head of Clinical Technologies, Tessella I was lucky enough to join a focus group at the recent 8th Annual SAS Health Care & Life Sciences Executive Conference (http://www.sas.com/news/preleases/hlsconf-clinicaltrials.html). The group comprising of selected pharmaceutical industry executives, [...]
Tessella is a gold sponsor of the 2012 Bio-IT World Conference taking place at the World Trade Centre in Boston on the 24th and 26th of April 2012. If you would like to have a prearranged meeting with Tessella at the event then please email info@tessella.com. To find out more about Bio-IT World Conference 2012, visit [...]
By Peter Mansell Growing implementation of adaptive clinical trials following the publication of draft guidance on adaptive designs by the US Food and Drug Administration in February 2010 is helping to ease regulatory concerns within industry about the approach, says eClinical solutions specialist Perceptive Informatics…read more
Researchers identify four cognitive biases that might be slowing drug discovery. By Courtney Andersen In an age of increasing financial and logistical pressures facing biotech and pharmaceutical companies, optimizing R&D success is a critical task. But in a commentary published last year in Drug Discovery Today, Andrew Chadwick of Tessella and Matthew Segall of Optibrium [...]
Matthew Segall, Optibrium Ltd., Cambridge, U.K. and Andrew Chadwick, Tessella plc, Burton upon Trent, U.K. When human biases distort drug discovery decision-making, software tools can guide thinking towards objective answers…read more
Optibrium, a provider of software solutions for drug discovery, and Tessella, the information technology and consulting services company and world leaders in digital preservation technology, published a new paper highlighting that scientists’ instincts may not always lead them to making good drug discovery decisions. The challenges of decision-making arise from the importance of multiple/conflicting criteria [...]
As pharma R&D leaders bring together their discovery and early development organizations they face tough decisions. How do you optimize project planning across a seamless R&D process? What is the right balance between risk, cost and value in the face of uncertainty? When and how should you deploy predictive technologies such as biomarkers? This webinar [...]
Tessella are proudly sponsoring the 6th Annual Biomarkers Congress taking place on February 23-24th, 2011 in Manchester, UK. Tom Parke, Head of Clinical Technologies at Tessella will be speaking at the event. His talk will be on Incorporating Biomarkers into Trial Designs. To find out more or to register on-line visit http://www.biomarkers-congress.com
